**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	09/847,208
Filing Date	May 1, 2001
First Named Inventor	Andrew SAXON et al.
Group/Art Unit	1644
Examiner Name	Phuong N. HUYNH
Attorney Docket Number	39754-0672A

Total Number of Pages in This Submission

ENCLOSURES (check all that apply)

- | | | |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment / Response
<input type="checkbox"/> After Final
<input type="checkbox"/> Version With Markings Showing Changes
<input type="checkbox"/> Affidavits/declaration(s) (UNSIGNED)
<input type="checkbox"/> Extension of Time Request
<input checked="" type="checkbox"/> Information Disclosure Statement with (PTO-1449)
<input type="checkbox"/> Declaration on Incorporation by Reference, including copy of Provisional Application 60/097,141
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53
<input type="checkbox"/> Copy of Notice | <input type="checkbox"/> Copy of an Assignment
<input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, by Assignee to Exclusion of Inventor Under 37 C.F.R. §3.71 With Revocation of Prior Powers
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Small Entity Statement
<input type="checkbox"/> Request for Refund | <input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> ADDITIONAL ENCLOSURE(S) (PLEASE IDENTIFY BELOW):
<input checked="" type="checkbox"/> 61 References Submitted and a Stamped Return Receipt Postcard |
|---|---|---|


Remarks

AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER, REFERENCING ATTORNEY'S DOCKET NO. 39754-0672A**SIGNATURE OF APPLICANT, ATTORNEY OR AGENT**

Firm or Individual name	HELLER EHRMAN WHITE & McAULIFFE LLP	LESLIE A. MOOI, Reg. No.: 37,047
	275 Middlefield Road, Menlo Park, California 94025	Telephone: (650) 324-7000 Facsimile: (650) 324-0638
Signature	<i>Leslie Mooi</i>	
Date	March 29, 2005	Customer Number: 25213

CERTIFICATE OF EXPRESS MAILINGI hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: **MAIL STOP AMENDMENT**, Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on this date: **March 29, 2005**Express Mail Label **EV 582 629 160 US**

Typed or printed name	Sandra Puljic		
Signature	<i>Sandra Puljic</i>	Date	3-29-2005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ANDREW SAXON et al.

Application Serial No. 09/847,208

Filed: May 1, 2001

For: **FUSION MOLECULES AND
TREATMENT OF IGE-MEDIATED
ALLERGIC DISEASES**

) Examiner: Huynh, Phuong N.

) Art Unit: 1644

) Attorney's Docket No. 39754-0672A

) Customer No. 25213

EXPRESS MAIL LABEL NO.: EV 582 629 160 US

DATE MAILED: March 29, 2005

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents

PO Box 1450

Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Form Supplemental PTO-1449 is enclosed and the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --

03/31/2005 GWORDOF1 00000024 081641 09047208

01 FC:1806 180.00 DA


- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☒ a fee of **\$180.00** as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of **\$180.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39754-0672A)**.

Respectfully submitted,

Dated: March 29, 2005

By: Leslie Mooi
Leslie Mooi (Reg. No. 37,047)

HELLER EHRMAN WHITE & McAULIFFE LLP
275 Middlefield Road
Menlo Park, CA 94025-3506
Telephone: (650) 324-7000 /Facsimile: (650) 324-0638
Customer No. 25213
SV 2112940 v1



Form PTO-1449

Attorney's Docket No.

39754-0672A

Application Serial No.

09/847,208

INFORMATION DISCLOSURE STATEMENT

Applicant(s) ANDREW SAXON et al.

Filing Date:

May 1, 2001

Group Art Unit:

1644

(use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.	10-1996	5,565,335	Capon et al.	435	69.7	
	2.	08-1999	5945294	Frank et al.	435	7.9	
	3.	05-1995	5,420,247	Gearing et al.	530	350	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation	
							YES	NO
	4.	12-19-1996	WO 96/40789	PCT	C07K	16/46		

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	5.	Antoniou, A. N., et al., "Control of Antigen Presentation by a Single Protease Cleavage Site", Immunity, Vol. 12, pp. 391-398, April, 2000.
	6.	Arm, J.P., et al., "Molecular Identification of a Novel Family of Human Ig Superfamily Members That Possess Immunoreceptor Tyrosine-Based Inhibition Motifs and Homology to the Mouse gp49B1 Inhibitory Receptor ^{1,2} ", J. Immunol., Vol. 159, pp 2342-2349, 1997.
	7.	Atwood, T. K., et al., "The Babel of Bioinformatics", Science, Vol. 290, No 5491, pp 471-473, October 2000
	8.	Bellmann, K., et al., "Potential risk of oral insulin with adjuvant for the prevention of Type I diabetes: a protocol effective in NOD mice may exacerbate disease in BB rats", Diabetologia, Vol. 41, pp 844-847, 1998.
	9.	Bielekova, B., et al., "Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand", Nat Med., Vol. 6, No. 10, pp 1167-75, October 2000.
	10.	Blanas, E. et al., "Induction of Autoimmune Diabetes by Oral Administration of Autoantigen", Science, Vol. 274, pp. 1707-1709, December 6, 1996.
	11.	Bridges, S. L., Jr., MD, PhD, et al., "T-cell Receptor Peptide Vaccination in the Treatment of Rheumatoid Arthritis", Emerging Therapies for Rheumatoid Arthritis, Vol. 24, Number 3, pp. 641-651, 1998.
	12.	Breiteneder, H, PhD, et al., "Complementary DNA cloning and expression in <i>Escherichia coli</i> of <i>Aln g I</i> , the major allergen in pollen of alder (<i>Alnus glutinosa</i>)", J Allergy Clin. Immunol., Vol. 90, No. 6, pp. 909-917, 1992.
	13.	Chaillous, L, et al., "Combined analysis of islet cell antibodies which cross-react with mouse pancreas, antibodies to the Mr 64,000 islet protein, and antibodies to glutamate decarboxylase in subjects at risk for IDDM", Diabetologia, Vol. 37, pp. 491-499, 1994.
	14.	Chaillous, L. et al., "Oral insulin administration and residual β -cell function in recent-onset type 1 diabetes: a multicentre randomized controlled trial", The Lancet, Vol. 356, pp 545-549, 2000.
	15.	Couzin, J., et al., "Diabetes' Brave New World", Science, Vol. 300, pp 1862-1865, June 2003.
	16.	Davidson, A., et al, "Autoimmune Diseases", N. Engl. J. Med., Vol. 345, No. 5, pp 340-350, August 2, 2001.
	17.	Dombrowicz, D., et al., "Anaphylaxis Mediated Through A Humanized High Affinity IgE Receptor", The Journal Of Immunology, Vol. 157, pp 1645-1651, 1996.


EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2112940 v1



Form PTO-1449		Attorney's Docket No. 39754-0672A	Application Serial No. 09/847,208
INFORMATION DISCLOSURE STATEMENT		Applicant(s) ANDREW SAXON et al.	
Use several sheets if necessary)		Filing Date: May 1, 2001	Group Art Unit: 1644
18.	Elias et al., Post translational Addition of an Argine Moiety to Acidic NH ₂ Termini of Proteins Is Required for Their Recognition by Ubiquitin-Protein Ligase", J. Biol. Chem., Vol. 265, No. 26, pp 15511-17, September 1990.		
19.	Gale, E. AM., "Oral tolerance and autoimmune diabetes—will hope triumph over experience?", The Lancet, Vol. 356, August 12, 2000.		
20.	Genain, C. P., et al., "Late Complications Of Immune Deviation Therapy in a Nonhuman Primate", Science, Vol. 274, December 20, 1996		
21.	Gold, D. P., et al., "T-Cell Receptor Peptides as Immunotherapy for Autoimmune Disease", Critical Reviews™ In Immunology, Vol. 17, pp 507-510, 1997.		
22.	Goodkin, D. E., et al., "A phase I trial of solubilized DR2:MBP ⁸⁴⁻¹⁰² (AG284) in multiple sclerosis", Neurology, Vol. 54, pp 1414-1420, 2000.		
23.	Haselden, B. M., et al., "Immunoglobulin E-Independent Major Histocompatibility Complex-Restricted T Cell Peptide Epitope-induced Late Asthmatic Reactions", J. Exp. Med., Vol. 189, No. 12, pp 1885-1894, June 21, 1999.		
24.	Helm, B. A., et al., "Identification of the High Affinity Receptor Binding Region in Human Immunoglobulin E", The Journal of Biological Chemistry, Vol. 271, No. 13, Issue of March 29, pp. 7494-7500, 1996.		
25.	Kappos, L., et al., "Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial", Nature Medicine, Vol. 6, No. 10, pp 1176-1182, October 2000.		
26.	Kepley, C. L., et al., "Negative regulation of FcεRI signaling by FcγRII costimulation in human blood basophils", Journal of Allergy and Clinical Immunology, Volume 106, Number 2, August 2000.		
27.	Kinet, J-P. "THE HIGH-AFFINITY IGE RECEPTOR (FcεRI): From Physiology to Pathology", Annu. Rev. Immunol., Vol. 17, pp 931-72, 1999.		
28.	Kisselev, A. F., "Proteasome Active Sites Allosterically Regulate Each Other, Suggesting A Cyclical Bite-Chew Mechanism For Protein Breakdown", Molecular Cell, Vol. 4, pp 395-402, September, 1999.		
29.	Luckey, C. J., et al., "Differences in the Expression of Human Class I MHC Alleles and Their Associated Peptides in the Presence of Proteasome Inhibitors", The Journal of Immunology, Vol. 167, pp 1212-1221, 2001.		
30.	Lyczak, J. B., et al., "Expression Of Novel Secreted Isoforms of Human Immunoglobulin E Proteins", The Journal of Biological Chemistry, Vol. 271, No. 7, Issue of February 16, pp. 3428-3436, 1996.		
31.	Marks, M. S. et al., "Protein Targeting by Tyrosine- and Di-leucine-based Signals: Evidence for Distinct Saturable Components", The Journal of Cell Biology", Vol. 135, No. 2, pp 341-354, October 1996.		
32.	McFarland, H. F., "Complexities in the Treatment of Autoimmune Disease", Science, Vol. 274, December 20, 1996.		
33.	Mikayama, T., et al., "Molecular cloning and functional expression of cDNA encoding glycosylation-inhibiting factor", Proc. Natl. Acad. Science, Vol. 90, pp 10056-10060, November 1993.		
34.	Mocci, S., et al., "The role of autoantigens in autoimmune disease", Current Opinion in Immunology, Vol. 12, pp 725-730, 2000.		


EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2112940 v1



Form PTO-1449		Attorney's Docket No. 39754-0672A	Application Serial No. 09/847,208
INFORMATION DISCLOSURE STATEMENT		Applicant(s) ANDREW SAXON et al.	
(use several sheets if necessary)		Filing Date: May 1, 2001	Group Art Unit: 1644
35.	Moreland, L. W., et al., "V β 17 T Cell Receptor Peptide Vaccination In Rheumatoid Arthritis: Results Of Phase I Dose Escalation Study", The Journal of Rheumatology, Vol. 23, No. 8, pp 1353-62, 1966.		
36.	Moreland, L. W., et al., "T Cell Receptor Peptide Vaccination in Rheumatoid Arthritis – A Placebo-Controlled Trial Using A Combination of V β 3, V β 14, and V β 17 Peptides", Arthritis & Rheumatism, Vol. 41, No. 11, pp. 1919-1929, November 1998.		
37.	Naquet, P., et al., "T Cell Autoreactivity To Insulin In Diabetic And Related Non-Diabetic Individuals", The Journal of Immunology, Vol. 140, No. 8, pp 2569-2578, April 15, 1988.		
38.	Nepom, G. T., et al., "Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65)", PNAS, Vol. 98, No. 4, pp 1763-1768, February 13, 2001.		
39.	Nepom, G. T., "Glutamic acid decarboxylase and other autoantigens in IDDM", Current Opinion in Immunology, Vol. 7, pp 825-830, 1995.		
40.	Ota, K., et al., "T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis", Nature, Vol. 346, pp 183-187, July 12, 1990.		
41.	Pamer, E., et al., "Mechanisms of MHC Class I—Restricted Antigen Processing", Annu. Rev. Immunol., Vol. 16, pp 323-358, 1998.		
42.	Pozzilli, P., et al., "No effect of oral insulin on residual beta-cell function in recent-onset Type I diabetes (the IMDIAB VII)", Diabetologia, Vol. 43, pp 1000-1004, 2000.		
43.	Rock, K. L., et al., "Degradation of Cell Proteins and the Generation of MHC Class I-Presented Peptides", Annu. Rev. Immunol., Vol. 17, pp 739-79, 1999.		
44.	Sharma, S. D., et al., "Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex—peptide complexes", Proc. Natl. Acad. Sci. USA, Vol. 88, pp 11465-11469, December 1991.		
45.	Sliedregt, L., et al., "Design and Synthesis of a Multivalent Homing Device for Targeting to Murine CD22", Bioorganic & Medicinal Chemistry, Vol. 9, pp 85-97, 2001.		
46.	Spack, E. G., et al., "Induction of Tolerance in Experimental Autoimmune Myasthenia Gravis with Solubilized MHC Class II: Acetylcholine Receptor Peptide Complexes", Journal of Autoimmunity, Vol. 8, pp 787-807, 1995.		
47.	Stryer, L. et al, Biochemistry, Third Edition, W. H. Freeman Company, New York, New York, pp 31-33, 1998.		
48.	Steinman, L. et al., "Antigen Specific Immunotherapy Of Multiple Sclerosis", Journal of Clinical Immunology, Vol. 21, No. 2, pp 93-98, 2001.		
49.	TePas, E. C., et al, "Immunotherapy of asthma and allergic diseases", Current Opinion in Pediatrics, Vol. 12, pp 574-578, 2000.		
50.	Tunon, J. M. et al., "Immunoglobines E et cellules de l'inflammation", Rev. Mal. Resp., Vol. 13, pp 27-36, 1996:		


EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2112940 v1



Form PTO-1449		Attorney's Docket No. 39754-0672A	Application Serial No. 09/847,208
INFORMATION DISCLOSURE STATEMENT		Applicant(s) ANDREW SAXON et al.	
(use several sheets if necessary)		Filing Date: May 1, 2001	Group Art Unit: 1644
51.	van Rossenberg, S. M. W., et al, "A Structure-Function Study of Ligand Recognition by CD22 β ", Journal of Biological Chemistry, Vol. 276, No. 16, Issue of April 20, pp 12967-12973, 2001.		
52.	Varshavsky, A., "The N-End Rule", Vol. 69, pp 725-735, May 29, 1992.		
53.	Villadangos, J. A., "Proteases involved in MHC class II antigen presentation", Immunological Reviews, Vol. 172, pp 109-120, 1999.		
54.	Villadangos, Jose A., "Proteolysis in MHC Class II Antigen Presentation: Who's in Charge?", Immunity, Vol. 12, pp 233-239, March 2000.		
55.	Warren, K.G., et al, "Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features", Proc. Natl. Acad. Sci. USA, Vol. 92, pp 11061-11065, November 1995.		
56.	Warren, K. G., "Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis", Journal of Neuroimmunology, Vol. 43, pp 87-96, 1993.		
57.	Warren, K. G., "Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid", Journal of Neuroimmunology, Vol. 39, pp 81-90, 1992.		
58.	Warren, K.G., et al, "Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P ₈₅ VVHFFKNIVTP ₉₆ in chronic progressive multiple sclerosis", Journal of Neurological Sciences, Vol. 152, pp 31-38, 1997.		
59.	Watts, C., "Antigen processing in the endocytic compartment", Current Opinion in Immunology", Vol. 13, pp 26-31, 2001.		
60.	Watts, C., "Capture and Processing of Exogenous Antigens for Presentation on MHC Molecules", Annu. Rev. Immunol., Vol. 15, pp 821-850, 1997.		
61.	Weiner, H. L., et al., "Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis", Science, Vol. 259, pp 1321-1324, February 26, 1993.		
62.	Wucherpennig, K. W., et al, "Recognition of the Immunodominant Myelin Basic Protein Peptide by Autoantibodies and HLA-DR2-restricted T Cell Clones from Multiple Sclerosis Patients", J. Clin. Invest., Vol. 100, No. 5, pp 1114-1122, September 1997.		
63.	Yodoi, J., et al, "Low affinity IgE receptors: regulation and functional roles in cell activation", Ige, Mast Cells and the Allergic Response, Wiley Chichester (Ciba Foundation Symposium 147) pp 133-153, 1989.		
64.	Yoon, J-W., et al, "Control of Autoimmune Diabetes in NOD Mice by GAD Expression or Suppression in β Cells", Science, Vol. 284, pp 1183-1187, May 14, 1999.		

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	